The 10-year study, led by Biomedical Research Centre-funded Professor Kathy Pritchard-Jones, followed 583 children with stage II or stage III Wilms’ tumour of intermediate risk type, which is the most common. The results showed that 96.5 per cent of children whose treatment included doxorubicin – which has been linked to irreversible heart problems later in life – survived for five years or more, compared with 95.8 per cent of children who did not receive the drug. Even though there was a slight increase in the risk of patients relapsing if they did not receive doxorubicin, these patients were successfully treated subsequently, meaning that overall survival rates were the same. The standard treatment for this type of Wilms’ tumour has now been changed to not give doxorubicin. This means that the majority of children now avoid the risk of long term heart problems.
The results have been published in the Lancet. Kathy Pritchard-Jones is a BRC funded researcher.